{
    "clinical_study": {
        "@rank": "127892", 
        "arm_group": [
            {
                "arm_group_label": "tofacitinib MR 11 mg Fed", 
                "arm_group_type": "Experimental", 
                "description": "tofacitinib modified release (MR) 11 mg tablet administered with food."
            }, 
            {
                "arm_group_label": "tofacitinib MR 11 mg Fasting", 
                "arm_group_type": "Experimental", 
                "description": "tofacitinib modified release (MR) 11 mg tablet administered without food."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the drug behavior and safety of a single dose of the 11 milligram\n      tofacitinib (CP-690,550) modified-release formulation in 24 healthy volunteers when taken\n      after eating a high fat meal (the effect of food). This will be compared to the drug\n      behavior and safety of a single dose of the 11 milligram tofacitinib (CP-690,550)\n      modified-release formulation when taken after a 10 hour fast."
        }, 
        "brief_title": "A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers and/or healthy females volunteers of non-childbearing\n             potential who are 18 to 55 years of age;\n\n          -  Healthy volunteers who are of Japanese or Western descent;\n\n          -  Healthy volunteers with no evidence of active or latent or inadequately treated\n             tuberculosis.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease;\n\n          -  Clinically significant infections within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084875", 
            "org_study_id": "A3921180"
        }, 
        "intervention": [
            {
                "arm_group_label": "tofacitinib MR 11 mg Fed", 
                "description": "A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.", 
                "intervention_name": "tofacitinib modified-release (MR) formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "tofacitinib MR 11 mg Fasting", 
                "description": "tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.", 
                "intervention_name": "tofacitinib modified-release (MR) formulation", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Food effect", 
            "pharmacokinetic", 
            "healthy volunteer"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921180&StudyName=A%20Study%20To%20Evaluate%20The%20Effect%20Of%20Food%20On%20The%20Behavior%20Of%20Tofacitinib%20Modified%20Release%2011%20Milligram%20Tablets%20In%20Healthy%20Western%20And%2"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open Label, Single Dose, 2-Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (MR) 11 Mg Tablets In Healthy Western And Japanese Volunteers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the curve from time zero to infinity", 
                "measure": "Area under the curve from time zero to infinity", 
                "safety_issue": "No", 
                "time_frame": "48 hours post dose"
            }, 
            {
                "description": "Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration", 
                "measure": "Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration", 
                "safety_issue": "No", 
                "time_frame": "48 hours post dose"
            }, 
            {
                "description": "Maximum Observed Plasma Concentration (Cmax)", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "48 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084875"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to peak concentration", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "48 hours post dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "48 hours post dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}